Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2024-11-18 Regulatory Filings
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
NFL BIOSCIENCES : LE MÉCANISME D’ACTION NOUVEAU ET DISRUPTIF DE NFL-101 POUR LE SEVRAGE TABAGIQUE PRÉSENTÉ AU CONGRÈS ANNUEL DE LA SOCIÉTÉ FRANCOPHONE DE TABACOLOGIE
Regulatory Filings Classification · 92% confidence The document is an announcement from NFL BIOSCIENCES regarding a presentation at the Annual Congress of the French-Speaking Society of Tabacology (CSFT) on November 28-29, 2024. It details the scientific findings about their drug candidate NFL-101, including results from previous clinical studies (CEST0, PRECESTO, CESTO II) and ongoing work (submission of CESTO II results for publication). This is not a full Annual Report (10-K), an Interim Report (IR), or a formal Earnings Release (ER). It is an announcement about scientific progress and presentation at a conference, which falls under general investor/corporate communication. Since it is a specific announcement about scientific data presentation and progress, and not a general regulatory filing (RNS) or a presentation document itself (IP), it best fits the category for general corporate updates or scientific disclosure. Given the options, it is a specific corporate announcement detailing scientific progress and upcoming presentation, which is often categorized as a general regulatory filing or an investor-focused update. Since it is not a formal financial report, dividend notice, or management change, and it is announcing scientific progress rather than attaching a formal report, 'Regulatory Filings' (RNS) serves as the most appropriate general category for non-standard, material corporate news, or 'Investor Presentation' (IP) if it were the presentation itself. However, this is a press release *about* a presentation. Given the context of scientific disclosure, 'Regulatory Filings' (RNS) is the most suitable fallback for material, non-standard corporate news that doesn't fit the specific financial/governance codes.
2024-11-18 French
NFL BIOSCIENCES: LEADERSHIP TEAM PREPARING THE NEXT STAGES IN ITS DEVELOPMENT
Board/Management Information Classification · 99% confidence The document explicitly details a change in the roles of the Chairman-Chief Executive Officer and the Managing Director following a Board of Directors meeting. Specifically, Bruno Lafont moved from Managing Director to Chairman-Chief Executive Officer, and Ignacio Faus moved from Chairman-Chief Executive Officer to Managing Director. This constitutes an announcement of changes in the company's board of directors or senior management. This directly matches the definition for Board/Management Information (MANG). The document length is short (3390 chars), but the content is the announcement itself, not a notice about an attached report.
2024-10-18 English
NFL BIOSCIENCES : L’ÉQUIPE DIRIGEANTE PRÉPARE LES PROCHAINES ÉTAPES DU DÉVELOPPEMENT
Board/Management Information Classification · 98% confidence The document explicitly details a change in the roles of the top executives (CEO and Deputy CEO) within the company's governance structure following a Board of Directors meeting. Key phrases include 'L'ÉQUIPE DIRIGEANTE PRÉPARE LES PROCHAINES ÉTAPES DU DÉVELOPPEMENT' (The management team prepares the next development steps) and the announcement that 'Bruno Lafont... est nommé Président Directeur général, et Ignacio Faus est nommé Directeur général délégué'. This directly corresponds to the definition of Board/Management Information.
2024-10-18 French
NFL BIOSCIENCES: EFFICACY VALIDATED THROUGH UPDATED ANALYSES FROM CESTO II FOR SMOKING CESSATION. SIGNIFICANT REDUCTION IN CRAVING. STRONG COMMERCIAL POTENTIAL CONFIRMED.
Regulatory Filings Classification · 85% confidence The document is a press release from NFL Biosciences announcing updated clinical trial results for their drug candidate NFL-101. It details the efficacy of the CESTO II study, including statistical data and comparisons to placebos, and discusses the commercial potential of the drug. It is not a formal financial report (10-K or IR), nor is it a regulatory filing or a simple announcement of a report. It falls under the category of a corporate announcement regarding clinical trial progress and business outlook, which is best classified as a Regulatory Filing (RNS) in the absence of a more specific 'Clinical Trial Results' category. Q3 2024
2024-10-08 English
NFL BIOSCIENCES : VALIDATION DE L’EFFICACITÉ PAR DES ANALYSES ACTUALISÉES DE CESTO II EN SEVRAGE TABAGIQUE. RÉDUCTION SIGNIFICATIVE DU CRAVING. FORT POTENTIEL COMMERCIAL CONFIRMÉ.
Investor Presentation Classification · 95% confidence The document is a detailed press release from NFL BIOSCIENCES announcing the definitive, updated results of their Phase 2 clinical study, CESTO II, for their smoking cessation drug candidate, NFL-101. It includes efficacy data (abstinence rates confirmed by cotinine levels), analysis of craving reduction (FTCQ-12 scores), commercial potential assessment, and a detailed reminder of the study methodology (Phase 2b, randomized, double-blind, 318 smokers). This content strongly aligns with the release of comprehensive clinical trial results and associated business commentary, which is characteristic of an Earnings Release (ER) or a detailed Investor Presentation (IP). Since it provides substantial, specific data updates following an initial announcement (mentioned as July 2024), and focuses heavily on the scientific validation and market potential, it fits best as a comprehensive update that goes beyond a simple 'highlights only' ER. However, given the depth of scientific detail, mechanism of action discussion, and comparison to existing treatments, it functions very much like an Investor Presentation (IP) designed to inform investors about the scientific progress and commercial outlook. It is not a formal regulatory filing like a 10-K or IR, nor is it a transcript or a simple announcement of a report (RPA). Between ER and IP, the structure and depth lean towards an Investor Presentation (IP) detailing the scientific and commercial narrative derived from the study results.
2024-10-08 French
NFL BIOSCIENCES : RAPPORT FINANCIER SEMESTRIEL au 30 juin 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Interim Financial Report) for the period ending June 30, 2024. It contains detailed management discussion and analysis (activity report), financial statements, and an audit review report. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-09-27 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.